Document Detail


Living related kidney transplantation without calcineurin inhibitors: initial experience in a Mexican center.
MedLine Citation:
PMID:  17164728     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We performed a prospective randomized trial comparing sirolimus/mycophenolate mofetil (MMF)/prednisone to cyclosporine/MMF/prednisone and selected induction therapy with basiliximab. Twenty patients received sirolimus (10 mg loading dose followed by 3 mg/m body surface area/day, keeping 24-hr trough levels at 10-15 ng/mL for six months and 5-10 ng/mL thereafter. Twenty-one patients began cyclosporine (4 to 8 mg/kg/day, keeping 12-hour trough levels at 150-300 ng/mL for 6 months and 100-200 ng/mL afterwards). Mean follow up was 15.8 months. One-year patient and graft survival was similar in both groups (>90%). Acute rejection rate was 16.6% in the sirolimus group and 5.2% in the cyclosporine group (P=NS). There were no differences in mean serum creatinine between groups. No patients who received basiliximab and had sirolimus target levels suffered acute rejection at one year. The sirolimus group had significantly higher cholesterol and triglycerides. A calcineurin inhibitor-free regimen using sirolimus produces comparable one-year transplant outcomes in living related kidney transplants compared to a calcineurin inhibitor regimen.
Authors:
Gustavo Martinez-Mier; Marco T Mendez-Lopez; Luis F Budar-Fernandez; Jorge Estrada-Oros; Regino Franco-Abaroa; Esteban George-Micelli; Luis Rios-Martinez; Gustavo F Mendez-Machado
Related Documents :
8629298 - Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection.
20586868 - Efficacy of antibiotic combination therapy in patients with active ulcerative colitis, ...
9135858 - Cyclophosphamide in severe steroid-resistant bronchiolitis obliterans organizing pneumo...
7772488 - Nodular prurigo responds to cyclosporin.
14703108 - Carbon dioxide laser vaporization of the inferior turbinate for allergic rhinitis: shor...
1740208 - Performance of cryopreserved pre-embryos obtained in in vitro fertilization cycles with...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Transplantation     Volume:  82     ISSN:  0041-1337     ISO Abbreviation:  Transplantation     Publication Date:  2006 Dec 
Date Detail:
Created Date:  2006-12-13     Completed Date:  2007-03-08     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0132144     Medline TA:  Transplantation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1533-6     Citation Subset:  IM    
Affiliation:
Department of Organ Transplantation, IMSS Adolfo Ruiz Cortines National Medical Center, Veracruz, Mexico. gmtzmier@ver.megared.net.mx
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Anti-Inflammatory Agents / therapeutic use*
Blood Chemical Analysis
Calcineurin / antagonists & inhibitors
Drug Therapy, Combination
Female
Graft Rejection / prevention & control*
Graft Survival
Humans
Immunosuppressive Agents / therapeutic use*
Kidney / physiology
Kidney Transplantation*
Living Donors*
Male
Mexico
Prednisone / therapeutic use*
Prospective Studies
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Immunosuppressive Agents; 53-03-2/Prednisone; EC 3.1.3.16/Calcineurin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  No influence of chromosome Y haplogroup variation in acute graft-versus-host disease in sardinia.
Next Document:  Ex vivo perfusion with mitomycin C containing solution prolongs heart graft survival in rats.